Sebastian Salentin

This study characterizes how aminoacyl-tRNA synthetases distinguish amino acids using computational analysis of crystallographic structures, revealing the role of binding site composition, non-covalent interactions, error correction, and steric effects.

This paper identifies ibrutinib as a VEGFR2 inhibitor through structure-based drug repositioning, revealing its polypharmacological action beyond BTK.

The paper identifies two distinct ATP binding motifs in aminoacyl tRNA synthetases (aaRS) and links their structural features to evolutionary hypotheses about the origin of these enzymes.